Previous close | 3.9900 |
Open | 4.0300 |
Bid | 2.9400 x 200 |
Ask | 5.0100 x 200 |
Day's range | 3.7950 - 4.1100 |
52-week range | 1.6600 - 6.8800 |
Volume | |
Avg. volume | 67,156 |
Market cap | 212.028M |
Beta (5Y monthly) | 1.50 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.0200 |
Earnings date | 06 May 2024 - 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 5.80 |
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematological models as monotherapy and provides improved depth and duration of response in combination with BTK/BCL2 inhibition Next Generation CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targe
Posters to highlight highly selective oral SMARCA2 degrader, potentially best-in-class CDK9 inhibitor and next-generation CDK4/6 inhibitorWILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-class CDK9 inhibitor and its next-generation CDK4/6 inhibitor, have been acc